依维莫司治疗晚期乳腺癌激素受体阳性患者中位生存期的影响因素分析

目的探究依维莫司治疗晚期乳腺癌激素受体(HR)阳性人表皮生长因子受体(HER-2)阴性患者中位生存期(mPFS)的影响因素。方法选择本院在2018年2月至2019年2月收治的98例采用依维莫司联合内分泌治疗的晚期HR(+)HER-2(-)乳腺癌患者,根据mPFS是否>3个月分为长期生存组(61例)与短期生存组(37例)。单因素分析影响mPFS的可能因素,进入多因素Logistic回归方程,总结影响晚期乳腺癌患者mPFS的可能因素。结果单因素分析显示,2组患者年龄、肿瘤类型、转移部位数目、既往化疗情况等因素均不会对mPFS造成影响(P>0.05),是否向远处转移、对内分泌治疗是否敏感对mPFS有明显影响(P<0.05);多因素分析显示,是否向远处转移、对内分泌治疗是否敏感均为影响晚期HR(+)HER-2(-)乳腺癌患者mPFS的相关危险因素(P<0.05)。结论内分泌治疗联合依维莫司可通过改善晚期HR(+)HER-2(-)乳腺癌患者的内分泌治疗耐药性,而延长其mPFS。

Factors influencing the median progression-free survival in HR(+)/HER-2(-) advanced breast cancer patients treated on everolimus

Objective To investigate the factors influencing the median progression-free survival(mPFS)in patients with hormone receptor-positive and human epidermal growth factor receptor-2 negative HR(+)/HER-2(-)advanced breast cancer treated with everolimus.Methods Included were 98 HR(+)/HER-2(-)advanced breast cancer patients treated with everolimus plus endocrine therapy in our hospital between February 2018 and Febru-ary 2019.Depending on a mPFS of three months,the patients were assigned to the long mPFS group(n=61)and the short mPFS group(n=37).Univariate analysis was used to identify potential factors that may be related to mPFS.These factors were fed into the multivariate Logistic regression equation,thereby we summarized on the po-tential factors affecting mPFS in patients with advanced breast cancer.Results Univariate analysis showed that the patient age,tumor type,number of metastatic lesions,and previous chemotherapy did not interfere with mPFS in either group(P>0.05).Distant metastasis and sensitivity to endocrine therapy may significantly affect the mPFS(P<0.05).Multivariate analysis showed that distant metastasis and sensitivity to endocrine therapy are risk factors that affect mPFS in patients with HR(+)/HER-2(-)advanced breast cancer(P<0.05).Conclusion In patients with HR(+)/HER-2(-)advanced breast cancer,endocrine therapy combined with everolimus can reduce the resistance to endocrine therapy,and prolong the median progression-free survival.